



PTO-1449 REPRODUCED  <div style="border: 1px solid black; border-radius: 50%; padding: 10px; display: inline-block; text-align: center;">                     INFORMATION DISCLOSURE CITATION                      IN AN APPLICATION                      MAR 21 2003                      March 17, 2003                      (Use several sheets if necessary)                 </div>				ATTORNEY DOCKET NO. 0148.1102-011		APPLICATION NO. 09/896,050	
APPLICANTS John Ghrayeb, David M. Knight and James E. Looney				FILING DATE June 29, 2001		GROUP 1644	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
AA	4,695,459	22 SEP 87	Steinman et al.	—	—		
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO		
AL	0 365 209 A2	25 APR 90	EPO	—	—		
AM	WO 91/09966	11 JUL 91	PCT	—	—		
AN	WO 91/09967	11 JUL 91	PCT	—	—		
AO	0 394 827	31 OCT 90	EPO	—	—		
AP	WO 90/12868	01 NOV 90	PCT	—	—		
AQ	WO 88/09181	01 DEC 88	PCT	—	—		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AR	Sun, L.K., et al., "Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A," <i>Proc. Natl. Acad. Sci. USA</i> , 84:214-218 (1987).						
AS	Morrison, S.L., et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains," <i>Proc. Natl. Acad. Sci. USA</i> , 81:6851-6855 (1984).						
AT	Landau, N.R., et al., "The Envelope Glycoprotein of the Human Immunodeficiency Virus Binds to the Immunoglobulin-like Domain of CD4," <i>Nature</i> , 334:159-162 (1988).						
AU	Wang, J., et al., "Atomic Structure of a Fragment of Human CD4 Containing Two Immunoglobulin-like Domains," <i>Nature</i> , 348:411-418 (1990).						
AV	Ryu, S.E., et al., "Crustal Structure of an HIV-binding Recombinant Fragment of Human CD4," <i>Nature</i> , 348:419-426 (1990).						
AW	Sattentau, Q.J., et al., "Epitopes of the CD4 Antigen and HIV Infection," <i>Science</i> , 234:1120-1123 (1986).						
AX	Peterson, A., et al., "Genetic Analysis of Monoclonal Antibody and HIV Binding Sites on the Human Lymphocyte Antigen CD4," <i>Cell</i> , 54:65-72 (1988).						
AY	Sattentau, Q.J., et al., "Structural Analysis of the Human Immunodeficiency Virus-binding Domain of CD4," <i>J. Exp. Med.</i> , 170:1319-1334 (1989).						
EXAMINER 				DATE CONSIDERED 5/28/2003			


RECEIVED  
 MAR 24 2003  
 TECH CENTER 1600/2900



PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,050
INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 17, 2003 (Use several sheets if necessary)		APPLICANTS John Ghrayeb, David M. Knight and James E. Looney	
		FILING DATE June 29, 2001	GROUP 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
(B)	AZ	Ashkenazi, A., et al., "Mapping the CD4 Binding Site for Human Immunodeficiency Virus by Alanine-Scanning Mutagenesis," <i>Proc. Natl. Acad. Sci. USA</i> , 87:7150-7154 (1990).	
	AR2	Healey, D., et al., "Novel Anti-CD4 Monoclonal Antibodies Separate Human Immunodeficiency Virus Infection and Fusion of CD4 <sup>+</sup> Cells From Virus Binding," <i>J. Exp. Med.</i> , 172:1233-1242 (1990).	
	AS2	Wofsy, D., et al., "Successful Treatment of Autoimmunity in NZB/NZW F <sub>1</sub> Mice With Monoclonal Antibody to L3T4" <i>J. Exp. Med.</i> , 161:378-391 (1985).	
	AT2	Ranges, G.E., et al., "Prevention of Type II Collagen-induced Arthritis by in vivo Treatment with Anti-L3T4," <i>J. Exp. Med.</i> , 162:1105-1110 (1985).	
	AU2	Wofsy, D., "Administration of Monoclonal, Anti-T Cell Antibodies Retards Murine Lupus in BXSB Mice," <i>J. Immunol.</i> , 136(12):4554-4560 (1986).	
	AV2	Hafler, D.A., et al., "Anti-CD4 and Anti-CD2 Monoclonal Antibody Infusions in Subjects with Multiple Sclerosis," <i>J. Immunol.</i> , 141(1):131-138 (1988).	
	AW2	Hom, et al., "The Progression of the Inflammation in Established Collagen-Induced Arthritis can be Altered by Treatments With Immunological or Pharmacological Agents Which Inhibit T Cell Activities," <i>Eur. J. Immunol.</i> , 18:881-888 (1988).	
	AX2	Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," <i>Laboratory Investigation</i> , 61(4):447-456 (1989).	
	AY2	Alters, S.E., "A Comparison of Rat and Rat-Mouse Chimeric Anti-Murine CD4 Antibodies for Use in Immunotherapy," (A Dissertation at Stanford University, May 1989).	
	AZ2	Alters, S.E., et al., "Comparison of Rat and Rat-Mouse Chimeric Anti-Murine CD4 Antibodies for Use in Immunotherapy," <i>FASEB J.</i> , 3(3):A492, Abstract No. 1546 (1989).	
	AR3	Alters, S.E., et al., "Comparison of Rat and Rat-Mouse Chimeric Anti-Murine CD4 Antibodies in vitro," <i>J. Immunol.</i> , 142(6):2018-2023 (1989).	
	AS3	Alters, S.E., et al., "Mechanisms of Anti-CD4-Mediated Depletion and Immunotherapy - A Study Using a Set of Chimeric Anti-CD4 Antibodies," <i>J. Immunol.</i> , 144(12):4587-4592 (1990).	
	AT3	Herzog, C., et al., "Monoclonal Anti-CD4 in Arthritis," <i>The Lancet</i> , 2(8573):1461-1462 (1987).	
	AU3	Herzog, C., et al., "Anti-CD4 Antibody Treatment of Patients with Rheumatoid Arthritis: I. Effect on Clinical Course and Circulating T Cells," <i>J. Autoimmunity</i> , 2:627-642 (1989).	
EXAMINER		DATE CONSIDERED	
			



RECEIVED

MAR 24 2003

TECH CENTER 1600/2900



PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,050
INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 17, 2003 (Use several sheets if necessary)		APPLICANTS John Ghrayeb, David M. Knight and James E. Looney	
		FILING DATE June 29, 2001	GROUP 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
187	AV3	Walker, C., et al., "Anti-CD4 Antibody Treatment of Patients with Rheumatoid Arthritis: II. Effect of in vivo Treatment on in vitro Proliferative Response of CD4 Cells," <i>J. Autoimmunity</i> , 2:643-649 (1989).	
	AW3	Oi, V.T., et al., "Chimeric Antibodies," <i>BioTechniques</i> , 4(3):214-221 (1986).	
	AX3	Morrison, S.L., et al., "Genetically Engineered Antibody Molecules: New Tools for Cancer Therapy," <i>Cancer Investigation</i> , 6(2):185-192 (1988).	
	AY3	Wood, G.S., et al., "Immunopathology of Mycosis Fungoides (MF) Patients Treated with Chimeric Anti-CD4 Antibody," <i>J. Cutaneous Pathology</i> , 16(5):330 (Abstract) (1989).	
	AZ3	Knox, J., et al., "A Phase I Clinical Trial with Chimeric Anti-CD4 Monoclonal Antibody in Patients with Mycosis Fungoides," <i>J. Cell Biochem.-Suppl.</i> 14 Part B:108, Abstract No. CE 513 (1990).	
	AR4	Reiter, C., et al., "In Vitro and In Vivo Characteristics of a Chimeric Human-Mouse Monoclonal CD4 Antibody," <i>Immunobiology</i> , 181(213):219-220 (1990).	
131	AS4	Trauneker, A., et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-Immunoglobulin Molecules," <i>Nature</i> , 339:68-70 (1989).	
	AT4	Waldmann, T.A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991).	
	AU4	Harris, W.J., and S. Emery, "Therapeutic Antibodies-The Coming of Age," <i>TIBTECH</i> , 11:42-44 (1993).	
	AV4	Hird, V. and A.A. Epenetos, "Immunotherapy with Monoclonal Antibodies," In: <i>Genes and Cancer</i> , Carney, D. et al. Eds. (John Wiley & Sons Ltd.; New York), Chapter 17, pp. 183-189 (1990).	
131	AW4	Dillman, R.O., "Human Antimouse and Antiglobulin Responses to Monoclonal Antibodies," <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , 3(1):1-15 (1990).	
131	AX4	Benjamin, R.J. et al., "Tolerance to Rat Monoclonal Antibodies, Implications for Serotherapy," <i>J. Exp. Med.</i> , 163:1539-1552 (1986).	
131	AY4	Herlyn, D. et al., "Specific Detection of Anti-Idiotypic Immune Responses in Cancer Patients Treated with Murine Monoclonal Antibody," <i>J. Immunol. Methods</i> , 85:27-38 (1985).	
131	AZ4	Shawler, D.L. et al., "Human Immune Response to Multiple Injections of Murine Monoclonal IgG," <i>J. Immunol.</i> , 135(2):1530-1535 (1985).	
131	AR5	Chatenoud, L. et al., "Restriction of the Human in vivo Immune Response Against the Mouse Monoclonal Antibody OKT3," <i>J. Immunol.</i> , 137(3):830-838 (1986).	
EXAMINER		DATE CONSIDERED.	
			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,098
INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 17, 2003 (attach several sheets if necessary)		APPLICANTS John Ghrayeb, David M. Knight and James E. Looney	
		FILING DATE June 29, 2001	GROUP 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
123)	AS5	Brüggemann, M. et al., "The Immunogenicity of Chimeric Antibodies," J. Exp. Med., 170:2153-2157 (1989).	
124)	AT5	Khazaeli, M.B. et al., "Pharmacokinetics and Immune Response of <sup>131</sup> I-Chimeric Mouse/Human B72.3 (Human $\gamma$ 4) Monoclonal Antibody in Humans," Cancer Res., 51:5461-5466 (1991).	
125)	AUS	Abbas A.K. et al., Cellular and Molecular Immunology, (W.B. Saunders Co.), page 153 (1991).	
126)	AV5	Weissenhorn, W. et al., "Combinatorial Functions of Two Chimeric Antibodies Directed to Human CD4 and One Directed to the $\alpha$ -Chain of the Human Interleukin-2 Receptor," Gene, 121: 271-278 (1992).	
127)	AWS	Weissenhorn, W. et al., "Structural Diversity of Monoclonal CD4 Antibodies and Their Capacity to Block the HIV GP120/CD4 Interaction," Hybridoma, 15(2):117-124 (1996).	
EXAMINER		DATE CONSIDERED	
			

RECEIVED  
MAR 24 2003  
FBI CENTER 1600/2300